Risk factors for severe outcomes for COVID-19 patients hospitalised in Switzerland during the first pandemic wave, February to August 2020: prospective observational cohort study.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
19 07 2021
Historique:
entrez: 29 7 2021
pubmed: 30 7 2021
medline: 10 8 2021
Statut: epublish

Résumé

As clinical signs of COVID-19 differ widely among individuals, from mild to severe, the definition of risk groups has important consequences for recommendations to the public, control measures and patient management, and needs to be reviewed regularly. The aim of this study was to explore risk factors for in-hospital mortality and intensive care unit (ICU) admission for hospitalised COVID-19 patients during the first epidemic wave in Switzerland, as an example of a country that coped well during the first wave of the pandemic. This study included all (n = 3590) adult polymerase chain reaction (PCR)-confirmed hospitalised patients in 17 hospitals from the hospital-based surveillance of COVID-19 (CH-Sur) by 1 September 2020. We calculated univariable and multivariable (adjusted) (1) proportional hazards (Fine and Gray) survival regression models and (2) logistic regression models for in-hospital mortality and admission to ICU, to evaluate the most common comorbidities as potential risk factors. We found that old age was the strongest factor for in-hospital mortality after having adjusted for gender and the considered comorbidities (hazard ratio [HR] 2.46, 95% confidence interval [CI] 2.33−2.59 and HR 5.6 95% CI 5.23−6 for ages 65 and 80 years, respectively). In addition, male gender remained an important risk factor in the multivariable models (HR 1.47, 95% CI 1.41−1.53). Of all comorbidities, renal disease, oncological pathologies, chronic respiratory disease, cardiovascular disease (but not hypertension) and dementia were also risk factors for in-hospital mortality. With respect to ICU admission risk, the pattern was different, as patients with higher chances of survival might have been admitted more often to ICU. Male gender (OR 1.91, 95% CI 1.58−2.31), hypertension (OR  1.3, 95% CI 1.07−1.59) and age 55–79 years (OR 1.15, 95% CI 1.06−1.26) are risk factors for ICU admission. Patients aged 80+ years, as well as patients with dementia or with liver disease were admitted less often to ICU. We conclude that increasing age is the most important risk factor for in-hospital mortality of hospitalised COVID-19 patients in Switzerland, along with male gender and followed by the presence of comorbidities such as renal diseases, chronic respiratory or cardiovascular disease, oncological malignancies and dementia. Male gender, hypertension and age between 55 and 79 years are, however, risk factors for ICU admission. Mortality and ICU admission need to be considered as separate outcomes when investigating risk factors for pandemic control measures and for hospital resources planning.

Sections du résumé

BACKGROUND
As clinical signs of COVID-19 differ widely among individuals, from mild to severe, the definition of risk groups has important consequences for recommendations to the public, control measures and patient management, and needs to be reviewed regularly.
AIM
The aim of this study was to explore risk factors for in-hospital mortality and intensive care unit (ICU) admission for hospitalised COVID-19 patients during the first epidemic wave in Switzerland, as an example of a country that coped well during the first wave of the pandemic.
METHODS
This study included all (n = 3590) adult polymerase chain reaction (PCR)-confirmed hospitalised patients in 17 hospitals from the hospital-based surveillance of COVID-19 (CH-Sur) by 1 September 2020. We calculated univariable and multivariable (adjusted) (1) proportional hazards (Fine and Gray) survival regression models and (2) logistic regression models for in-hospital mortality and admission to ICU, to evaluate the most common comorbidities as potential risk factors.
RESULTS AND DISCUSSION
We found that old age was the strongest factor for in-hospital mortality after having adjusted for gender and the considered comorbidities (hazard ratio [HR] 2.46, 95% confidence interval [CI] 2.33−2.59 and HR 5.6 95% CI 5.23−6 for ages 65 and 80 years, respectively). In addition, male gender remained an important risk factor in the multivariable models (HR 1.47, 95% CI 1.41−1.53). Of all comorbidities, renal disease, oncological pathologies, chronic respiratory disease, cardiovascular disease (but not hypertension) and dementia were also risk factors for in-hospital mortality. With respect to ICU admission risk, the pattern was different, as patients with higher chances of survival might have been admitted more often to ICU. Male gender (OR 1.91, 95% CI 1.58−2.31), hypertension (OR  1.3, 95% CI 1.07−1.59) and age 55–79 years (OR 1.15, 95% CI 1.06−1.26) are risk factors for ICU admission. Patients aged 80+ years, as well as patients with dementia or with liver disease were admitted less often to ICU.
CONCLUSION
We conclude that increasing age is the most important risk factor for in-hospital mortality of hospitalised COVID-19 patients in Switzerland, along with male gender and followed by the presence of comorbidities such as renal diseases, chronic respiratory or cardiovascular disease, oncological malignancies and dementia. Male gender, hypertension and age between 55 and 79 years are, however, risk factors for ICU admission. Mortality and ICU admission need to be considered as separate outcomes when investigating risk factors for pandemic control measures and for hospital resources planning.

Identifiants

pubmed: 34324698
doi: 10.4414/smw.2021.20547
pii: Swiss Med Wkly. 2021;151:w20547
doi:
pii:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

w20547

Auteurs

Filipe Maximiano Sousa (F)

Swiss Federal Office of Public Health, Bern, Switzerland / Veterinary Public Health Institute, University of Bern, Switzerland.

Maroussia Roelens (M)

Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland.

Brian Fricker (B)

Swiss Federal Office of Public Health, Bern, Switzerland / Veterinary Public Health Institute, University of Bern, Switzerlan.

Amaury Thiabaud (A)

Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland.

Anne Iten (A)

Service of Prevention and Infection Control, Directorate of Medicine and Quality, University Hospital Geneva, HUG, Geneva, Switzerland.

Alexia Cusini (A)

Department of Infectious Diseases, Cantonal Hospital Graubuenden, Chur, Switzerland.

Domenica Flury (D)

Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, Switzerland.

Michael Buettcher (M)

Paediatric Infectious Diseases, Department of Paediatrics, Children's Hospital, Cantonal Hospital Lucerne, Switzerland.

Franziska Zukol (F)

Paediatric Infectious Diseases, Department of Paediatrics, Cantonal Hospital Winterthur, Switzerland.

Carlo Balmelli (C)

Infection Control Programme, EOC Hospitals, Ticino, Switzerland.

Petra Zimmermann (P)

Faculty of Science and Medicine, University of Fribourg, Switzerland / Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland.

Nicolas Troillet (N)

Service of Infectious Diseases, Central Institute, Valais Hospitals, Sion, Switzerland.

Danielle Vuichard-Gysin (D)

Division of Infectious Diseases and Hospital Hygiene, Thurgau Hospital Group Münsterlingen and Frauenfeld, Switzerland.

Peter W Schreiber (PW)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich, Switzerland.

Sara Bernhard-Stirnemann (S)

Children's Hospital Aarau, Switzerland.

Sarah Tschudin-Sutter (S)

Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel and University of Basel, Switzerland.

Yvonne Nussbaumer-Ochsner (Y)

Clinic for Internal Medicine, Cantonal Hospital, Hospitals Schaffhausen, Switzerland.

Rami Sommerstein (R)

Department of Infectious Diseases, Bern University Hospital (Inselspital), Bern, Switzerland / Infectious Diseases and Hospital Hygiene, Hirslanden Central Switzerland, Lucerne, Switzerland.

Roman Gaudenz (R)

Internal Medicine and Infectiology, Cantonal Hospital Nidwalden, Stans, Switzerland.

Jonas Marschall (J)

Department of Infectious Diseases, Bern University Hospital (Inselspital), Bern, Switzerland.

Laurence Senn (L)

Service of Preventive Medicine, Lausanne University Hospital, CHUV, Lausanne, Switzerland.

Céline Gardiol (C)

Swiss Federal Office of Public Health, Bern, Switzerland.

Olivia Keiser (O)

Institute of Global Health, Faculty of Medicine, University of Geneva, Switzerland.

Gertraud Schüpbach (G)

Swiss Federal Office of Public Health, Bern, Switzerland / Veterinary Public Health Institute, University of Bern, Switzerland.

Monica Wymann (M)

Swiss Federal Office of Public Health, Bern, Switzerland.

Beatriz Vidondo (B)

Swiss Federal Office of Public Health, Bern, Switzerland / Veterinary Public Health Institute, University of Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH